Is NCT05208762 recruiting in Orange, CA?

Yes, NCT05208762 is currently recruiting participants at its Orange, CA location. This carcinoma, non-small-cell lung clinical trial is actively enrolling qualified participants.

How do I join the carcinoma, non-small-cell lung clinical trial in Orange?

To join this clinical trial in Orange, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Orange clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Carcinoma, Non-Small-Cell Lung Clinical Trial in Orange, CA

About This Carcinoma, Non-Small-Cell Lung Study in Orange

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable). This study will have five parts. Parts A and B of the study will find out how much PF-08046054/SGN- PDL1V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe PF-08046054/SGN-PDL1V is and if it works to treat solid tumor cancers. In Part D and E, participants will be given PF-08046054/SGN-PDL1V with pembrolizumab to find out how safe this combination is and if it works to treat solid tumor cancers.

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Who Can Participate

Inclusion Criteria

Parts A and B:

Participants must have one of the following histologically- or cytologically-confirmed metastatic or unresectable solid tumor types

Non-small cell lung cancer (NSCLC)

Head and neck squamous cell carcinoma (HNSCC) (except nasopharyngeal cancer)

Esophageal squamous cell carcinoma (SCC)

Triple negative breast cancer (TNBC)

Participants must have disease that is relapsed or refractory, that has progressed on approved therapies, be intolerant to or refused such therapies, or such and therapies are contraindicated and in the judgement of the investigator, should have no appropriate SoC therapeutic option

Participants must have PD-L1 expression based on historical testing

Participants must have disease that is relapsed or refractory or be intolerant to SoC therapies and must have one of the following tumor types

Participants with HNSCC must have histologically or cytologically-confirmed HNSCC

Participants must have histologically or cytologically-confirmed NSCLC. Participants with SCC and non--SCC histology are eligible. Note: Participants with a neuroendocrine component or histology are not eligible.

Esophageal SCC

Pancreatic cancer

Hepatocellular carcinoma

Gastric cancer

Endometrial cancer

Participants must have been previously tested for PD-L1 expression and should have PD-L1 expression ≥1 or \<1 by CPS or TPS based on historical testing

Part D and Part E:

Participants must have histologically or cytologically-confirmed disease of the HNSCC or NSCLC

Participants must have PD-L1 expression based on historical testing

Participants with NSCLC; PD-L1 expression ≥ 1% by TPS

Participants with HNSCC; PD--L1 expression ≥1 by CPS

Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

Measurable disease per RECIST v1.1 at baseline

Exclusion Criteria

History of another malignancy within 3 years of first dose of study treatment or any evidence of residual disease from a previously diagnosed malignancy.

Known active central nervous system metastases. Participants with previously-treated brain metastases may participate provided they:

Are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment

Have no new or enlarging brain metastases

And are off of corticosteroids prescribed for symptoms associate with brain metastases for at least 7 days prior to first dose of study treatment

Lepto-meningeal disease

Prior treatment with an anti-PD-L1 agent within less than 5 half-lives. This duration of time will vary according to the half-life of the specific agent.

Previous receipt of an monomethylauristatin E (MMAE)-containing agent.

Pre-existing neuropathy ≥Grade 2 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0. There are additional inclusion criteria. The study center will determine if criteria for participations are met.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Orange?

Yes, this clinical trial (NCT05208762) has an active research site in Orange, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Carcinoma, Non-Small-Cell Lung Treatment Options in Orange, CA

If you're searching for carcinoma, non-small-cell lung treatment options in Orange, CA, this clinical trial (NCT05208762) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Orange research site is actively enrolling participants for this clinical trial. You'll receive care from experienced carcinoma, non-small-cell lung specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all carcinoma, non-small-cell lung clinical trials near you to find additional studies recruiting in your area.

Carcinoma, Non-Small-Cell Lung Clinical Trial in Orange, CA

Expert Care in Orange

IRB Approved

No-Cost Care

Apply for This Orange Location

Why Participate?

Simple Process